Elitone, a non-invasive, innovative pelvic health product, will be accessible through the NHS nationwide, signalling major progress for women’s health in the UK.
12 million women in the UK experience urinary incontinence, costing the NHS almost £2bn every year.
Elidah, a US medical health company, has secured a partnership with the NHS to provide Trusts throughout the UK with Elitone, a non-invasive, innovative solution for pelvic health and incontinence.
Through HealthTrust Europe, a public sector procurement partner, the NHS has approved Elitone as a supplier for pelvic healthcare, signalling a major moment for women’s health in the UK.
From 1st March 2025, Elitone has been made available across 217 Trusts in the UK, offering a home delivery service of the products to help women who suffer with stress urinary incontinence, alongside a prescription service. The easy-to-use device will be available for healthcare professionals to access through the HealthTrust Europe Continence Goods and Services 2024 framework, which can also be located on the nationwide framework platform – Framespan.
Elitone is a solution that doesn’t involve exercises, invasive vaginal insertion treatment or surgery. Certified for use in Europe, the product is FDA-cleared in the USA, doctor-backed and helping tens of thousands of women who suffer with stress or mixed urinary incontinence to regain bladder control and confidence with life enhancing results in as little as six weeks.
In the UK, a staggering 42% of women reportedly suffer from bladder incontinence, although this figure is believed to be even higher, as many feel too ashamed to seek help or don’t realise they can do something about it. It’s reported that the average woman spends £600 every year on incontinence solutions while the NHS spends £1